Cellectis S.A. (NASDAQ:CLLS) was downgraded by Zacks Investment Research from a “hold” rating to a “strong sell” rating in a research report issued on Tuesday.
According to Zacks, “Cellectis SA is a gene-editing company. The company focused on developing immunotherapies based on gene edited engineered CAR-T cells. Cellectis SA is based in Paris, France. “
A number of other equities research analysts have also issued reports on the company. SunTrust Banks, Inc. restated a “hold” rating and issued a $20.00 price target on shares of Cellectis in a research report on Friday, October 6th. Jefferies Group LLC restated a “buy” rating and issued a $47.00 price target on shares of Cellectis in a research report on Tuesday, September 26th. Nomura dropped their price target on Cellectis from $49.00 to $43.00 and set a “buy” rating for the company in a research report on Wednesday, September 6th. Wells Fargo & Company restated an “outperform” rating and issued a $40.00 price target (up from $33.00) on shares of Cellectis in a research report on Tuesday, September 5th. Finally, BidaskClub upgraded Cellectis from a “strong sell” rating to a “sell” rating in a research report on Wednesday, August 23rd. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company’s stock. Cellectis has an average rating of “Hold” and an average price target of $39.00.
Cellectis (CLLS) traded up 0.21% during midday trading on Tuesday, hitting $28.10. The stock had a trading volume of 58,557 shares. Cellectis has a 12-month low of $16.09 and a 12-month high of $32.46. The company’s market cap is $1.01 billion. The firm has a 50-day moving average of $28.15 and a 200-day moving average of $28.15.
ILLEGAL ACTIVITY WARNING: “Cellectis S.A. (CLLS) Rating Lowered to Strong Sell at Zacks Investment Research” was first reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://www.chaffeybreeze.com/2017/10/17/cellectis-s-a-clls-rating-lowered-to-strong-sell-at-zacks-investment-research.html.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in CLLS. Sphera Funds Management LTD. lifted its holdings in Cellectis by 27.6% in the second quarter. Sphera Funds Management LTD. now owns 203,764 shares of the biotechnology company’s stock valued at $5,261,000 after acquiring an additional 44,100 shares during the last quarter. Balyasny Asset Management LLC acquired a new position in Cellectis in the second quarter valued at approximately $719,000. Williams Jones & Associates LLC acquired a new position in Cellectis in the second quarter valued at approximately $244,000. Wells Fargo & Company MN lifted its holdings in Cellectis by 132.1% in the second quarter. Wells Fargo & Company MN now owns 9,550 shares of the biotechnology company’s stock valued at $247,000 after acquiring an additional 5,435 shares during the last quarter. Finally, Eqis Capital Management Inc. lifted its holdings in Cellectis by 27.2% in the second quarter. Eqis Capital Management Inc. now owns 10,687 shares of the biotechnology company’s stock valued at $276,000 after acquiring an additional 2,287 shares during the last quarter. Hedge funds and other institutional investors own 14.82% of the company’s stock.
Cellectis Company Profile
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.
Receive News & Ratings for Cellectis S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis S.A. and related companies with MarketBeat.com's FREE daily email newsletter.